Hot Biotech Stocks To Watch For 2019

Investment company Stonepine Capital Management, LLC buys Recro Pharma, SciClone Pharmaceuticals, Novelion Therapeutics, Ophthotech, Enanta Pharmaceuticals, Veracyte, BioDelivery Sciences International, Sucampo Pharmaceuticals, Cardiome Pharma, Trinity Biotech PLC, sells Tobira Therapeutics, Cutera, Derma Sciences, Pacira Pharmaceuticals during the 3-months ended 2016-12-31, according to the most recent filings of the investment company, Stonepine Capital Management, LLC. As of 2016-12-31, Stonepine Capital Management, LLC owns 20 stocks with a total value of $146 million. These are the details of the buys and sells.

New Purchases: SCLN, NVLN, OPHT, ENTA, VCYT, BDSI, SCMP, TRIB, MNK, Added Positions: REPH, CRME, ALIM, ALR, VCEL, CPIX, DRRX, JNP, Reduced Positions: CUTR, AVIR, Sold Out: TBRA, DSCI, PCRX,

For the details of Stonepine Capital Management, LLC’s stock buys and sells, go to

These are the top 5 holdings of Stonepine Capital Management, LLCRecro Pharma Inc (REPH) – 2,874,317 shares, 15.85% of the total portfolio. Shares added by 145.54%Alere Inc (ALR) – 360,000 shares, 9.6% of the total portfolio. Shares added by 25.59%SciClone Pharmaceuticals Inc (SCLN) – 1,249,200 shares, 9.23% of the total portfolio. New PositionViveve Medical Inc (VIVE) – 2,599,711 shares, 9.1% of the total portfolio. Novelion Therapeutics Inc (NVLN) – 1,524,034 shares, 8.78% of the total portfolio. New PositionNew Purchase: SciClone Pharmaceuticals Inc (SCLN)

Stonepine Capital Management, LLC initiated holdings in SciClone Pharmaceuticals Inc. The purchase prices were between $8.65 and $10.8, with an estimated average price of $10. The stock is now traded at around $9.40. The impact to the portfolio due to this purchase was 9.23%. The holdings were 1,249,200 shares as of 2016-12-31.

Hot Biotech Stocks To Watch For 2019: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Paul Ausick]

    ArQule Inc. (NASDAQ: ARQL) dropped about 23% Friday, to post a new 52-week low of $1.13 after closing at $1.47 on Thursday. The stock’s 52-week high is $2.17. Volume was about 15 times the daily average of around 150,000 shares. The biopharmaceutical company said this morning that a phase 3 trial of a cancer drug did not meet the primary endpoint of improving overall survival.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on ArQule (ARQL)

    For more information about research offerings from Zacks Investment Research, visit

Hot Biotech Stocks To Watch For 2019: ARIAD Pharmaceuticals Inc.(ARIA)

Advisors’ Opinion:

  • [By Lisa Levin]

    Healthcare shares gained around 0.73 percent in trading on Monday. Meanwhile, top gainers in the sector included Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA), and VCA Inc (NASDAQ: WOOF).

Hot Biotech Stocks To Watch For 2019: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Chris Lange]

    Biogen Inc. (NASDAQ: BIIB) had its short interest increase to 2.63 million shares from the previous 2.36 million. The stock closed Friday at $305.20, within a 52-week range of $223.02 to $333.65.

  • [By Chris Lange]

    Short interest in Biogen Inc. (NASDAQ: BIIB) increased to 3.50 million shares from the previous 3.16 million. The stock recently traded at $262.15, within a 52-week range of $244.28 to $370.57.

  • [By Ben Levisohn]

    Biogen (BIIB) tumbled to the bottom of the S&P 500 today after getting cut by two analysts.

    Agence France-Presse/Getty Images

    Biogen dropped 4.7% to $278.96 at 4:19 p.m. today, while the S&P 500 declined 0.2% to 2,381.38.

    Leerinks Geoffrey Porges cited the “slower than expected ramp for Spinraza” in cutting Biogen to Market Perform from Outperform, while Morgan Stanly’s Matthew Harrison wrote that his decision to cut Biogen to Market Weight from Overweight was “not a downside call, but a timing call.”

    Biogen’s market capitalization fell to $60.2 billion today from $63.2 billion yesterday. It reported net income of $3.7 billion on sales of $10.2 billion in 2016.

    Barron’s Teresa Rivas recommended buying Biogen in December after the company released positive trial data on its Alzheimer’s drug.

  • [By Ben Levisohn]

    Biogen (BIIB) has dropped 2.2% to $286.16 after getting cut to Market Perform from Outperform at Leerink, and to Equal Weight from Overweight at Morgan Stanley.

  • [By Brian Orelli]

    Shares of Ionis Pharmaceuticals (NASDAQ:IONS) ended the day down 10.6% after an earnings reportfrom partner Biogen (NASDAQ:BIIB) started the day on a sour note. Then shares dropped even further midday after data was releasedfor IONIS-HTTRx, a treatment for Huntington’s disease. Biogen managed to end the day in the green, up 1.1%.

Hot Biotech Stocks To Watch For 2019: Medivation Inc.(MDVN)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Medivation (MDVN) has soared 20% to $80.41 after agreeing to be purchased for $14 billion, or $81.50 a share, by Pfizer (PFE). Pfizer has declined 0.7% to $34.75.

  • [By Lisa Levin]

    Shares of Medivation Inc (NASDAQ: MDVN) got a boost, shooting up 24 percent to $46.35 amid word of a new report from Bloomberg, saying the company is working with bankers to defend itself against preliminary interest of a takeover. However, Reuters separately reported the company is working with JPMorgan to handle interest from other companies, but said Medivation has no interest in selling itself.

  • [By Scott Rubin]

    Big gainers on the day included Intersil Corp (NASDAQ: ISIL), which jumped 20 percent on news of a buyout, and Medivation (NASDAQ: MDVN), which added 20 percent on a deal with Pfizer (NYSE: PFE) related to its cancer drug. Cotiviti Holdings Inc (NYSE: COTV) lost around 9 percent in the wake of a mid-day sell-off and Marathon Oil Corporation (NYSE: MRO) fell 7 percent in the wake of a management shakeup.

Leave a Reply

Your email address will not be published. Required fields are marked *